WebIf there are any changes in your situation (new insurance, a change of address, upcoming travel, etc), we can help you find ways to avoid treatment interruptions. If you need additional information and support, we can also direct you to patient advocacy and support groups. “We’ll be with you every step of the way.” Husband and father of 3 Web24 feb. 2024 · Kiniksa Pharmaceuticals has an overall rating of 2.5 out of 5, based on over 19 reviews left anonymously by employees. 35% of employees would recommend working at Kiniksa Pharmaceuticals to a friend and 33% have a positive outlook for the business.
Kiniksa Pharmaceuticals Reviews - Glassdoor
Web23 jan. 2024 · Kiniksa Pharmaceuticals Financials. Summary financials. Revenue (Q3, 2024)$99.1M Net income (Q3, 2024)$224.1M Cash (Q3, 2024)$175.8M EBIT (Q3, 2024)$46.4M Enterprise value $795.4M. Competitors and similar companies. YiChang HEC ChangJiang Pharmaceutical. Healthcare - Public. AGC Biologics. Web5 aug. 2024 · HAMILTON, Bermuda, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and ... drukwerkconcurrent
Kiniksa Pharmaceuticals (KNSA) Price To Free Cash Flow
Web15 nov. 2024 · KINIKSA PHARMACEUTICALS (FRANCE) SARL: Statut INSEE: INSCRITE depuis le 06/05/2024: Statut RCS: INSCRITE au greffe de Nanterre depuis le 07/06/2024: SIREN: 851731596: SIRET (siège) 85173159600017: Numéro TVA intracommunautaire : FR42851731596: Numéro RCS: 851 731 596 R.C.S. Nanterre: Adresse: 63T AV … WebKiniksa Pharmaceuticals (uk), Ltd. was incorporated as Private limited Company on 6 December 2024, with address Whitefriars 11th Floor, Lewins Mead, Bristol, United Kingdom, BS1 2NT. The company's SIC is 21100 - Manufacture of basic pharmaceutical products. and the status of this company is Active now. Web9 apr. 2024 · Firstly, we acknowledge that Kiniksa Pharmaceuticals has a significantly high ROE. Second, a comparison with the average ROE reported by the industry of 21% also doesn't go unnoticed by us. This likely paved the way for the modest 13% net income growth seen by Kiniksa Pharmaceuticals over the past five years. growth drukwerk concert